Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced mouse model of Parkinson's disease

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 8, 2011, Pages 1291-1296

  Li, Shen ^a,b   Pu, Xiao Ping ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Kaempferol; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; GLUTATHIONE PEROXIDASE; KAEMPFEROL; MALONALDEHYDE; SELEGILINE; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; ATAXIA; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GLUTATHIONE PEROXIDASE; KAEMPFEROLS; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; SUPEROXIDE DISMUTASE;

EID: 80051512571     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.1291     Document Type: Article

References (40)

1. Kurosaki R., Muramatsu Y., Kato H., Araki T., Pharmacol. Biochem. Behav., 78, 143-153 (2004).
2. Sowell R. A., Owen J. B., Butterfield D. A., Ageing Res. Rev., 8, 1-17 (2009).
3. Schmidt N., Ferger B., J. Neural Transm., 108, 1263-1282 (2001).
4. Watanabe Y., Himeda T., Araki T., Med. Sci. Monit., 11, RA17-RA23 (2005).
5. Olanow C. W., Obeso J. A., Stocchi F., Lancet Neurol., 5, 677-687 (2006).
6. Filomeni G., Graziani I., De Zio D., Dini L., Centonze D., Rotilio G., Ciriolo M. R., Neurobiol. Aging (2010) (PubMed PMID: 20594614).
7. Sulzer D., Zecca L., Neurotox. Res., 1, 181-195 (2000).
8. Hattoria N., Wanga M., Taka H., Fujimura T., Yoritaka A., Kubo S., Mochizuki H., Parkinsonism Relat. Disord., 15 (Suppl. 1), S35-S38 (2009).
9. Kono Y., Fridovich I., J. Biol. Chem., 257, 5751-5754 (1982).
10. Miller R. L., James-Kracke M., Sun G. Y., Sun A. Y., Neurochem. Res., 34, 55-65 (2009).
11. Zuk M., Kulma A., Dymińska L., Szołtysek K., Prescha A., Hanuza J., Szopa J., BMC Biotechnol., 11, 10 (2011) (PubMed PMID: 21276227).
12. Nirmala P., Ramanathan M., Eur. J. Pharmacol., 654, 75-79 (2011).
13. Schroeter H., Williams R. J., Matin R., Iversen L., Rice-Evans C. A., Free Radic. Biol. Med., 29, 1222-1233 (2000).
14. Schroeter H., Spencer J. P., Rice-Evans C., Williams R. J., Biochem. J., 358, 547-557 (2001).
15. Ishige K., Schubert D., Sagara Y., Free Radic. Biol. Med., 30, 433-446 (2001).
16. Kim Y., Park E. J., Kim J., Kim Y., Kim S. R., Kim Y. Y., J. Nat. Prod., 64, 75-78 (2001).
17. Qu W., Fan L., Kim Y. C., Ishikawa S., Iguchi-Ariga S. M., Pu X. P., Ariga H., J. Pharmacol. Sci., 110, 191-200 (2009).
18. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., Kuwana Y., Psychopharmacology (Berlin), 147, 90-95 (1999).
19. Rozas G., Lopéz-Martín E., Guerra M. J., Labandeira-García J. L., J. Neurosci. Methods, 83, 165-175 (1998).
20. Sommer B., Barbieri S., Hofele K., Wiederhold K., Probst A., Mistl C., Danner S., Kauffmann S., Spooren W., Tolnay M., Bilbe G., Kafmann S., Caromi P., Ruegg M. A., Ruegg M. A., van der Putten H., Exp. Gerontol., 35, 1389-1403 (2000).
21. Shiotsuki H., Yoshimi K., Shimo Y., Funayama M., Takamatsu Y., Ikeda K., Takahashi R., Kitazawa S., Hattori N., J. Neurosci. Methods, 189, 180-185 (2010).
22. Sedelis M., Schwarting R. K., Huston J. P., Behav. Brain Res., 125, 109-125 (2001).
23. Geng X., Tian X., Tu P., Pu X., Eur. J. Pharmacol., 564, 66-74 (2007).
24. Richardson J. R., Caudle W. M., Wang M., Dean E. D., Pennell K. D., Miller G. W., FASEB J., 20, 1695-1697 (2006).
25. Ahmad M., Saleem S., Ahmad A. S., Ansari M. A., Yousuf S., Hoda M. N., Islam F., Hum. Exp. Toxicol., 24, 137-147 (2005).
26. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
27. Friedlander A. H., Mahler M., Norman K. M., Ettinger R. L., J. Am. Dent. Assoc., 140, 658-669 (2009).
28. Youdim M. B., Bakhle Y. S., Br. J. Pharmacol., 147 (Suppl. 1), S287-S296 (2006).
29. Muralikrishnan D., Samantaray S., Mohanakumar K. P., Synapse, 50, 7-13 (2003).
30. Carder R. K., Jackson D., Morris H. J., Lund R. D., Zigmond M. J., Exp. Neurol., 105, 251-259 (1989).
31. Bloem B. R., Irwin I., Buruma O. J., Haan J., Roos R. A., Tetrud J. W., Langston J. W., J. Neurol. Sci., 97, 273-293 (1990).
32. Heikkila R. E., Hess A., Duvoisin R. C., Science, 224, 1451-1453 (1984).
33. Schwarting R. K., Huston J. P., Pharmacol. Biochem. Behav., 41, 675-682 (1992).
34. Ishikawa S., Taira T., Takahashi-Niki K., Niki T., Ariga H., Iguchi-Ariga S. M., J. Biol. Chem., 285, 39718-39731 (2010).
35. Hosp J. A., Pekanovic A., Rioult-Pedotti M. S., Luft A. R., J. Neurosci., 31, 2481-2487 (2011).
36. Freeman B. A., Crapo J. D., Lab. Invest., 47, 412-426 (1982).
37. Jenner P., Olanow C. W., Neurology, 47 (Suppl. 3), S161-S170 (1996).
38. Graham D. G., Arch. Pathol. Lab. Med., 103, 359-362 (1979).
39. Sloley B. D., Urichuk L. J., Morley P., Durkin J., Shan J. J., Pang P. K., Coutts R. T., J. Pharm. Pharmacol., 52, 451-459 (2000).
40. Sundström E., Jonsson G., Eur. J. Pharmacol., 110, 293-299 (1985).